Investigation of the effect of dual antithrombotic therapy with prasugrel in patients with atrial fibrillation after drug-eluting stent implantation for coronary artery disease
- Conditions
- Atrial fibrillation Coronary artery disease
- Registration Number
- JPRN-UMIN000047503
- Lead Sponsor
- Chiba University
- Brief Summary
In AF patients undergoing PCI, DAT was associated with lower incidence of MACE and major bleed- ing events compared with TAT. In comparison of P2Y12i, there might be no significant difference in the incidence of MACE and bleeding events between prasugrel-based DAT and clopidogrel-based DAT.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 949
Not provided
1. PCI with two stent technique for bifurcation lesion 2. history of stent thrombosis 3. mechanical valve or bioprosthetic valve 4. cardiogenic shock 5. history of stroke, major surgery, gastrointestinal bleeding within 1 month 6. hemorrhagic disease or diathesis 7. severe renal dysfunction 8. severe lever dysfunction 9. allergy for warfarin, dabigatran, rivaroxaban, apixaban, edoxaban, or prasugrel 10. pregnancy 11. scheduled for surgery
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Major adverse cardiovascular events (all-cause death, non-fatal myocardial infarction, stent thrombosis, unplanned revascularization, stroke)
- Secondary Outcome Measures
Name Time Method